Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|January 9, 2023
Multi-analyte liquid biopsies for molecular pathway guided personalized treatment selection in advanced refractory cancers: A clinical utility pilot studyDarshana Patil, Dadasaheb Akolkar, Rajnish Nagarkar, et al.
Clinical Drug Investigation|June 27, 2024
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III StudyM V T Krishna Mohan, Arpitkumar Prajapati, Rushabh Kothari, et al.
JAMA Oncology|September 18, 2015
First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical TrialSant P Chawla, Zsuzsanna Papai, Guzel Mukhametshina, et al.
Cancer Reports (Hoboken, N.J.)|November 19, 2024
Development of a Serum Metabolome-Based Test for Early-Stage Detection of Multiple CancersRajnish Nagarkar, Mamillapalli Gopichand, Suparna Kanti Pal, et al.
Oncotarget|October 15, 2019
Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trialRajnish Nagarkar, Darshana Patil, Timothy Crook, et al.
BMC Cancer|February 2, 2022
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumabDaniil L Stroyakovskiy, Natalya V Fadeeva, Marina P Matrosova, et al.
Lancet (London, England)|April 3, 2022
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in IndiaAkash Khobragade, Suresh Bhate, Vijendra Ramaiah, et al.
Oncotarget|November 23, 2020
Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapyRajnish Nagarkar, Darshana Patil, Sewanti Limaye, et al.
South Asian Journal of Cancer|December 25, 2025
Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 StudyDinesh Chandra Doval, Tanveer Maksud, Rajnish Nagarkar, et al.
Frontiers in Molecular Medicine|August 1, 2024
Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory CancersTimothy Crook, Darshana Patil, Rajnish Nagarkar, et al.
Pageof 3